Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus apatinib in PD-1–pretreated unresectable hepatocellular carcinoma
ChiCTR2600119061Phase 4Not yet recruiting
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab and Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Yantai Yuhuangding Hospital. Primary endpoint: Objective response rate. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600119061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119061.